Establishment of a humanized mouse model of keloid diseases following the migration of patient immune cells to the lesion: Patient-derived keloid xenograft (PDKX) model

Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid dis...

Full description

Saved in:
Bibliographic Details
Published inExperimental & molecular medicine Vol. 55; no. 8; pp. 1713 - 1719
Main Authors Lee, A Ram, Lee, Seon-Yeong, Choi, Jeong Won, Um, In Gyu, Na, Hyun Sik, Lee, Jung Ho, Cho, Mi-La
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.08.2023
Springer Nature B.V
Nature Publishing Group
Subjects
13/107
13/31
13/51
14/19
38/77
64/60
692/308/1426
692/420/2780/2152/1566/1618
82/80
96/21
Animal models
Biomedical and Life Sciences
Biomedicine
Chemokines
Helper cells
Hypoxia-inducible factor 1a
Immunodeficiency
Inflammation
Interleukin 17
Interleukin 2 receptors
Lesions
Leukocyte migration
Leukocytes (mononuclear)
Lymphocytes T
Medical Biochemistry
Microenvironments
Molecular Medicine
Patients
Quality of life
Scars
Skin
Stem Cells
Transplantation
Xenografts
Online AccessGet full text

Cover

Abstract Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders. Dermatology: A model for studying severe scars An improved animal model could lead to new treatments for keloids, abnormally heightened scarring responses that can occur after recovery from skin injury. These poorly understood scars occur only occur in humans, and existing animal models are based on immunodeficient mice. This is a serious drawback, given that immune cell invasion appears to be an important contributor to keloid formation. Researchers led by Mi La Cho and Jung Ho Lee at The Catholic University of Korea, Seoul, have devised an improved model that addresses this limitation. Their approach involves infusing mice with human T cells before introducing a graft of patient-derived keloid tissue. These animals subsequently develop scars that resemble human keloids much more closely than those in prior models, offering a powerful tool for studying these enigmatic lesions.
AbstractList Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders.
Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders.Dermatology: A model for studying severe scarsAn improved animal model could lead to new treatments for keloids, abnormally heightened scarring responses that can occur after recovery from skin injury. These poorly understood scars occur only occur in humans, and existing animal models are based on immunodeficient mice. This is a serious drawback, given that immune cell invasion appears to be an important contributor to keloid formation. Researchers led by Mi La Cho and Jung Ho Lee at The Catholic University of Korea, Seoul, have devised an improved model that addresses this limitation. Their approach involves infusing mice with human T cells before introducing a graft of patient-derived keloid tissue. These animals subsequently develop scars that resemble human keloids much more closely than those in prior models, offering a powerful tool for studying these enigmatic lesions.
Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders.Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders.
Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders. An improved animal model could lead to new treatments for keloids, abnormally heightened scarring responses that can occur after recovery from skin injury. These poorly understood scars occur only occur in humans, and existing animal models are based on immunodeficient mice. This is a serious drawback, given that immune cell invasion appears to be an important contributor to keloid formation. Researchers led by Mi La Cho and Jung Ho Lee at The Catholic University of Korea, Seoul, have devised an improved model that addresses this limitation. Their approach involves infusing mice with human T cells before introducing a graft of patient-derived keloid tissue. These animals subsequently develop scars that resemble human keloids much more closely than those in prior models, offering a powerful tool for studying these enigmatic lesions.
Abstract Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders.
Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders. Dermatology: A model for studying severe scars An improved animal model could lead to new treatments for keloids, abnormally heightened scarring responses that can occur after recovery from skin injury. These poorly understood scars occur only occur in humans, and existing animal models are based on immunodeficient mice. This is a serious drawback, given that immune cell invasion appears to be an important contributor to keloid formation. Researchers led by Mi La Cho and Jung Ho Lee at The Catholic University of Korea, Seoul, have devised an improved model that addresses this limitation. Their approach involves infusing mice with human T cells before introducing a graft of patient-derived keloid tissue. These animals subsequently develop scars that resemble human keloids much more closely than those in prior models, offering a powerful tool for studying these enigmatic lesions.
Author Lee, Seon-Yeong
Choi, Jeong Won
Um, In Gyu
Na, Hyun Sik
Lee, Jung Ho
Lee, A Ram
Cho, Mi-La
Author_xml – sequence: 1
  givenname: A Ram
  surname: Lee
  fullname: Lee, A Ram
  organization: Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea
– sequence: 2
  givenname: Seon-Yeong
  surname: Lee
  fullname: Lee, Seon-Yeong
  organization: Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea
– sequence: 3
  givenname: Jeong Won
  surname: Choi
  fullname: Choi, Jeong Won
  organization: Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea
– sequence: 4
  givenname: In Gyu
  surname: Um
  fullname: Um, In Gyu
  organization: Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea
– sequence: 5
  givenname: Hyun Sik
  surname: Na
  fullname: Na, Hyun Sik
  organization: Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea
– sequence: 6
  givenname: Jung Ho
  surname: Lee
  fullname: Lee, Jung Ho
  email: tfm0822@catholic.ac.kr
  organization: Department of Plastic and Reconstructive Surgery, College of Medicine, The Catholic University of Korea
– sequence: 7
  givenname: Mi-La
  orcidid: 0000-0001-5715-3989
  surname: Cho
  fullname: Cho, Mi-La
  email: iammila@catholic.ac.kr
  organization: Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37524866$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAUhiNURC_wAixQJDZlEfA1ttkgVApUVKILkNhZjnMy48GJp3amXJ6Ix8SZTKHtopvEsv_znd8-_2GxN4QBiuIpRi8xovJVwoSIukKEVggjxqv6QXFAkCJVzTDdu7HeLw5TWiFEOBPsUbFPBSdM1vVB8ec0jabxLi17GMYydKUpl5veDO43tGUfNgnytwU_HX0HH1xbti6BSZDKLngffrhhUY7LLHOLaEYXhkm6zqsJ6Pp-M0BpwftUjmEr9JCy6nV5MWuqFqK7yt12-J8whEzqxvL44t2nby_m_o-Lh53xCZ7s_kfF1_enX04-VuefP5ydvD2vLGd4rASFhhnDLW-lwchi2QI0HVa1UKrpCJKGABaYNg2xSNRcKG4U5bjGqoPG0qPibOa2waz0OrrexF86GKe3GyEutImjsx50S8BYUTfUUslACmWVlFRxBVjRDtWZ9WZmrTdND63Nl43G34LePhncUi_Clc7TFAxzmQnHO0IMlxtIo-5dmh7TDJBno4lkLN9MkqnZ8zvSVdjEIb9VVnEleM3YBHx209I_L9eJyAI5C2wMKUXotHXjdqzZofPZmp7Cp-fw6Rw-vQ2fnkrJndJr-r1FdC5KWTwsIP63fU_VXxXp7nY
CitedBy_id crossref_primary_10_1039_D4BM00005F
crossref_primary_10_1007_s00403_024_03352_y
crossref_primary_10_1016_j_cellsig_2024_111275
crossref_primary_10_1016_j_jid_2024_06_1274
crossref_primary_10_1016_j_bbadis_2025_167790
crossref_primary_10_1089_wound_2023_0203
crossref_primary_10_1016_j_bjps_2023_09_006
crossref_primary_10_3390_ijms242015475
Cites_doi 10.1111/1346-8138.12116
10.1006/jsre.1993.1132
10.4049/jimmunol.0802626
10.1146/annurev-pathol-052016-100332
10.1155/2020/3608372
10.1016/j.ijsu.2006.04.007
10.1371/journal.pone.0007798
10.1097/00005373-198905000-00023
10.1152/ajprenal.00016.2008
10.1038/s41598-021-84982-4
10.1164/rccm.200502-244OC
10.2147/JIR.S312091
10.1136/gut.2005.068593
10.1111/j.1365-2249.2009.03933.x
10.1007/s00403-009-1014-y
10.2174/187152807780832265
10.1001/archotol.1991.01870220125023
10.1016/j.ajpath.2018.04.005
10.3389/fimmu.2022.888719
10.1084/jem.175.2.503
10.3389/fimmu.2019.01810
10.1371/journal.pone.0075600
10.3109/03008209109152161
10.1111/j.1524-475X.2006.00193.x
10.1097/SLA.0000000000002926
10.3389/fimmu.2020.603187
10.3181/00379727-179-RC3
10.1155/2011/345803
10.3389/fimmu.2021.810290
10.1371/journal.pone.0060335
10.1007/s10753-019-01148-1
10.1111/j.1524-475X.2000.00371.x
10.1089/wound.2018.0828
10.1002/ar.1092250303
10.1111/j.1365-2133.2010.10048.x
10.1002/art.39443
10.1016/j.jid.2015.11.008
10.1016/j.det.2013.11.002
10.1155/2013/423147
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s12276-023-01045-6
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
Publicly Available Content Database
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 2092-6413
EndPage 1719
ExternalDocumentID oai_doaj_org_article_d2eac76b3c384e879c9883959e193f06
PMC10474158
37524866
10_1038_s12276_023_01045_6
Genre Journal Article
GrantInformation_xml – fundername: National Research Foundation of Korea (NRF)
  grantid: 2020R1F1A1075541
  funderid: https://doi.org/10.13039/501100003725
– fundername: National Research Foundation of Korea (NRF)
  grantid: 2020R1F1A1075541
– fundername: ;
  grantid: 2020R1F1A1075541
GroupedDBID ---
0R~
29G
2WC
3V.
5-W
53G
5GY
7X7
87B
88E
8FE
8FH
8FI
8FJ
8JR
9ZL
AAJSJ
ABUWG
ACGFO
ACGFS
ACPRK
ACSMW
ACYCR
ADBBV
AENEX
AFKRA
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
C1A
C6C
CCPQU
DIK
DU5
E3Z
EBLON
EBS
EF.
EJD
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
LK8
M1P
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
TR2
UKHRP
W2D
XSB
AASML
AAYXX
CITATION
OVT
PHGZM
PHGZT
NPM
7XB
8FK
AARCD
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c541t-73eb4aa5c5d8a10c18deebf196799bf208a2e1713bb2c0765795a9351619febc3
IEDL.DBID AAJSJ
ISSN 2092-6413
1226-3613
IngestDate Wed Aug 27 01:21:47 EDT 2025
Thu Aug 21 18:36:23 EDT 2025
Thu Jul 10 22:14:05 EDT 2025
Wed Aug 13 04:20:17 EDT 2025
Thu Jan 02 22:51:51 EST 2025
Tue Jul 01 04:10:32 EDT 2025
Thu Apr 24 23:06:03 EDT 2025
Fri Feb 21 02:40:06 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-73eb4aa5c5d8a10c18deebf196799bf208a2e1713bb2c0765795a9351619febc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-5715-3989
OpenAccessLink https://www.nature.com/articles/s12276-023-01045-6
PMID 37524866
PQID 2859756448
PQPubID 2041975
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_d2eac76b3c384e879c9883959e193f06
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10474158
proquest_miscellaneous_2844679826
proquest_journals_2859756448
pubmed_primary_37524866
crossref_citationtrail_10_1038_s12276_023_01045_6
crossref_primary_10_1038_s12276_023_01045_6
springer_journals_10_1038_s12276_023_01045_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20230800
2023-08-01
2023-Aug-01
20230801
PublicationDateYYYYMMDD 2023-08-01
PublicationDate_xml – month: 8
  year: 2023
  text: 20230800
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
– name: Seoul
PublicationTitle Experimental & molecular medicine
PublicationTitleAbbrev Exp Mol Med
PublicationTitleAlternate Exp Mol Med
PublicationYear 2023
Publisher Nature Publishing Group UK
Springer Nature B.V
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Springer Nature B.V
– name: Nature Publishing Group
References Sandulache, Parekh, Li-Korotky, Dohar, Hebda (CR4) 2007; 15
Supp (CR25) 2019; 8
Shih, Bayat (CR3) 2010; 302
Lee (CR5) 2020; 43
Li (CR32) 2021; 12
King (CR30) 2009; 157
Lee (CR14) 2022; 13
Jagadeesan, Bayat (CR23) 2007; 5
Wang (CR34) 2020; 11
Steinmetz (CR20) 2009; 183
Hammerich, Heymann, Tacke (CR16) 2011; 2011
Nangole, Ouyang, Anzala, Ogengo, Agak (CR19) 2021; 14
Syed (CR27) 2011; 164
Ishiko (CR11) 2013; 40
Herndon (CR12) 2018; 268
Seo, Lee, Jung (CR24) 2013; 2013
Nirodi (CR18) 2000; 8
Zhang (CR35) 2018; 188
Ashcroft, Syed, Bayat (CR28) 2013; 8
Walsh (CR29) 2017; 12
Tang (CR10) 2020; 2020
Choi, Kim, Ha, Park (CR26) 2021; 11
Lemaire (CR13) 2016; 68
Marra (CR38) 2005; 54
Shetlar, Shetlar, Hendricks, Kischer (CR6) 1985; 179
Shin (CR33) 2016; 136
Kischer, Pindur, Shetlar, Shetlar (CR8) 1989; 29
Friedman (CR21) 1993; 55
Zhang (CR36) 2009; 4
Tary-Lehmann, Saxon (CR31) 1992; 175
Tesch (CR37) 2008; 294
Lei (CR15) 2016; 34
Pignatti (CR17) 2006; 173
Tan, Khumalo, Bayat (CR1) 2019; 10
Shetlar, Shetlar, Kischer, Pindur (CR7) 1991; 26
Xia, Frangogiannis (CR39) 2007; 6
Kischer, Sheridan, Pindur (CR40) 1989; 225
Waki, Crumley, Jakowatz (CR9) 1991; 117
Ud-Din, Bayat (CR2) 2014; 32
Pan, Chen, Huang, Yao, Ma (CR22) 2013; 8
CS Nirodi (1045_CR18) 2000; 8
Y Li (1045_CR32) 2021; 12
EY Waki (1045_CR9) 1991; 117
M Tary-Lehmann (1045_CR31) 1992; 175
P Pignatti (1045_CR17) 2006; 173
R Lemaire (1045_CR13) 2016; 68
F Syed (1045_CR27) 2011; 164
KJ Ashcroft (1045_CR28) 2013; 8
SY Lee (1045_CR5) 2020; 43
NC Walsh (1045_CR29) 2017; 12
DW Friedman (1045_CR21) 1993; 55
SY Lee (1045_CR14) 2022; 13
CW Kischer (1045_CR40) 1989; 225
MH Choi (1045_CR26) 2021; 11
GH Tesch (1045_CR37) 2008; 294
B Shih (1045_CR3) 2010; 302
D Herndon (1045_CR12) 2018; 268
X Pan (1045_CR22) 2013; 8
MA King (1045_CR30) 2009; 157
CW Kischer (1045_CR8) 1989; 29
OM Steinmetz (1045_CR20) 2009; 183
ZC Wang (1045_CR34) 2020; 11
Q Zhang (1045_CR36) 2009; 4
J Zhang (1045_CR35) 2018; 188
F Marra (1045_CR38) 2005; 54
S Tan (1045_CR1) 2019; 10
MR Shetlar (1045_CR6) 1985; 179
MR Shetlar (1045_CR7) 1991; 26
J Jagadeesan (1045_CR23) 2007; 5
L Hammerich (1045_CR16) 2011; 2011
FW Nangole (1045_CR19) 2021; 14
Z Tang (1045_CR10) 2020; 2020
S Ud-Din (1045_CR2) 2014; 32
VC Sandulache (1045_CR4) 2007; 15
DM Supp (1045_CR25) 2019; 8
T Ishiko (1045_CR11) 2013; 40
L Lei (1045_CR15) 2016; 34
Y Xia (1045_CR39) 2007; 6
BF Seo (1045_CR24) 2013; 2013
JU Shin (1045_CR33) 2016; 136
References_xml – volume: 40
  start-page: 380
  year: 2013
  end-page: 383
  ident: CR11
  article-title: Chondroitinase injection improves keloid pathology by reorganizing the extracellular matrix with regenerated elastic fibers
  publication-title: J. Dermatol.
  doi: 10.1111/1346-8138.12116
– volume: 55
  start-page: 214
  year: 1993
  end-page: 222
  ident: CR21
  article-title: Regulation of collagen gene expression in keloids and hypertrophic scars
  publication-title: J. Surg. Res.
  doi: 10.1006/jsre.1993.1132
– volume: 183
  start-page: 4693
  year: 2009
  end-page: 4704
  ident: CR20
  article-title: CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0802626
– volume: 12
  start-page: 187
  year: 2017
  end-page: 215
  ident: CR29
  article-title: Humanized mouse models of clinical disease
  publication-title: Annu. Rev. Pathol.
  doi: 10.1146/annurev-pathol-052016-100332
– volume: 2020
  start-page: 3608372
  year: 2020
  ident: CR10
  article-title: Wubeizi ointment suppresses keloid formation through modulation of the mTOR pathway
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2020/3608372
– volume: 34
  start-page: 14
  year: 2016
  end-page: 22
  ident: CR15
  article-title: Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis
  publication-title: Clin. Exp. Rheumatol.
– volume: 5
  start-page: 278
  year: 2007
  end-page: 285
  ident: CR23
  article-title: Transforming growth factor beta (TGFbeta) and keloid disease
  publication-title: Int. J. Surg.
  doi: 10.1016/j.ijsu.2006.04.007
– volume: 4
  start-page: e7798
  year: 2009
  ident: CR36
  article-title: Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0007798
– volume: 29
  start-page: 672
  year: 1989
  end-page: 677
  ident: CR8
  article-title: Implants of hypertrophic scars and keloids into the nude (athymic) mouse: viability and morphology
  publication-title: J. Trauma
  doi: 10.1097/00005373-198905000-00023
– volume: 294
  start-page: F697
  year: 2008
  end-page: F701
  ident: CR37
  article-title: MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy
  publication-title: Am. J. Physiol. Renal Physiol.
  doi: 10.1152/ajprenal.00016.2008
– volume: 11
  year: 2021
  ident: CR26
  article-title: A selective small-molecule inhibitor of c-Met suppresses keloid fibroblast growth in vitro and in a mouse model
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-84982-4
– volume: 173
  start-page: 310
  year: 2006
  end-page: 317
  ident: CR17
  article-title: Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.200502-244OC
– volume: 14
  start-page: 2465
  year: 2021
  end-page: 2470
  ident: CR19
  article-title: Multiple cytokines elevated in patients with keloids: is it an indication of auto-inflammatory disease?
  publication-title: J. Inflamm. Res.
  doi: 10.2147/JIR.S312091
– volume: 54
  start-page: 1679
  year: 2005
  end-page: 1681
  ident: CR38
  article-title: Renaming cytokines: MCP-1, major chemokine in pancreatitis
  publication-title: Gut
  doi: 10.1136/gut.2005.068593
– volume: 157
  start-page: 104
  year: 2009
  end-page: 118
  ident: CR30
  article-title: Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex
  publication-title: Clin. Exp. Immunol.
  doi: 10.1111/j.1365-2249.2009.03933.x
– volume: 302
  start-page: 319
  year: 2010
  end-page: 339
  ident: CR3
  article-title: Genetics of keloid scarring
  publication-title: Arch. Dermatol. Res.
  doi: 10.1007/s00403-009-1014-y
– volume: 6
  start-page: 101
  year: 2007
  end-page: 107
  ident: CR39
  article-title: MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy
  publication-title: Inflamm. Allergy Drug Targets
  doi: 10.2174/187152807780832265
– volume: 117
  start-page: 1177
  year: 1991
  end-page: 1181
  ident: CR9
  article-title: Effects of pharmacologic agents on human keloids implanted in athymic mice. A pilot study
  publication-title: Arch. Otolaryngol. Head Neck Surg.
  doi: 10.1001/archotol.1991.01870220125023
– volume: 188
  start-page: 1693
  year: 2018
  end-page: 1702
  ident: CR35
  article-title: IL-17 promotes scar formation by inducing macrophage infiltration
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2018.04.005
– volume: 13
  start-page: 888719
  year: 2022
  ident: CR14
  article-title: IL-17 Induces autophagy dysfunction to promote inflammatory cell death and fibrosis in keloid fibroblasts via the STAT3 and HIF-1alpha dependent signaling pathways
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.888719
– volume: 175
  start-page: 503
  year: 1992
  end-page: 516
  ident: CR31
  article-title: Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.175.2.503
– volume: 10
  start-page: 1810
  year: 2019
  ident: CR1
  article-title: Understanding keloid pathobiology from a quasi-neoplastic perspective: less of a scar and more of a chronic inflammatory disease with cancer-like tendencies
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.01810
– volume: 8
  start-page: e75600
  year: 2013
  ident: CR28
  article-title: Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0075600
– volume: 26
  start-page: 23
  year: 1991
  end-page: 36
  ident: CR7
  article-title: Implants of keloid and hypertrophic scars into the athymic nude mouse: changes in the glycosaminoglycans of the implants
  publication-title: Connect. Tissue Res.
  doi: 10.3109/03008209109152161
– volume: 15
  start-page: 122
  year: 2007
  end-page: 133
  ident: CR4
  article-title: Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis
  publication-title: Wound Repair Regen.
  doi: 10.1111/j.1524-475X.2006.00193.x
– volume: 268
  start-page: 431
  year: 2018
  end-page: 441
  ident: CR12
  article-title: Reduced postburn hypertrophic scarring and improved physical recovery with yearlong administration of oxandrolone and propranolol
  publication-title: Ann. Surg.
  doi: 10.1097/SLA.0000000000002926
– volume: 11
  start-page: 603187
  year: 2020
  ident: CR34
  article-title: The roles of inflammation in keloid and hypertrophic scars
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.603187
– volume: 179
  start-page: 549
  year: 1985
  end-page: 552
  ident: CR6
  article-title: The use of athymic nude mice for the study of human keloids
  publication-title: Proc. Soc. Exp. Biol. Med.
  doi: 10.3181/00379727-179-RC3
– volume: 2011
  start-page: 345803
  year: 2011
  ident: CR16
  article-title: Role of IL-17 and Th17 cells in liver diseases
  publication-title: Clin. Dev. Immunol.
  doi: 10.1155/2011/345803
– volume: 12
  start-page: 810290
  year: 2021
  ident: CR32
  article-title: The polygenic map of keloid fibroblasts reveals fibrosis-associated gene alterations in inflammation and immune responses
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.810290
– volume: 8
  start-page: e60335
  year: 2013
  ident: CR22
  article-title: Transforming growth factor beta1 induces the expression of collagen type I by DNA methylation in cardiac fibroblasts
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0060335
– volume: 43
  start-page: 664
  year: 2020
  end-page: 672
  ident: CR5
  article-title: IL-17 induced stromal cell-derived factor-1 and profibrotic factor in keloid-derived skin fibroblasts via the STAT3 pathway
  publication-title: Inflammation
  doi: 10.1007/s10753-019-01148-1
– volume: 8
  start-page: 371
  year: 2000
  end-page: 382
  ident: CR18
  article-title: Chemokine and chemokine receptor expression in keloid and normal fibroblasts
  publication-title: Wound Repair Regen.
  doi: 10.1111/j.1524-475X.2000.00371.x
– volume: 8
  start-page: 77
  year: 2019
  end-page: 89
  ident: CR25
  article-title: Animal models for studies of keloid scarring
  publication-title: Adv. Wound Care (New Rochelle)
  doi: 10.1089/wound.2018.0828
– volume: 225
  start-page: 189
  year: 1989
  end-page: 196
  ident: CR40
  article-title: Use of nude (athymic) mice for the study of hypertrophic scars and keloids: vascular continuity between mouse and implants
  publication-title: Anat. Rec.
  doi: 10.1002/ar.1092250303
– volume: 164
  start-page: 83
  year: 2011
  end-page: 96
  ident: CR27
  article-title: Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy
  publication-title: Br. J. Dermatol.
  doi: 10.1111/j.1365-2133.2010.10048.x
– volume: 68
  start-page: 473
  year: 2016
  end-page: 483
  ident: CR13
  article-title: Resolution of skin fibrosis by neutralization of the antifibrinolytic function of plasminogen activator inhibitor 1
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.39443
– volume: 136
  start-page: 507
  year: 2016
  end-page: 515
  ident: CR33
  article-title: TSLP is a potential initiator of collagen synthesis and an activator of CXCR4/SDF-1 axis in keloid pathogenesis
  publication-title: J. Investig. Dermatol.
  doi: 10.1016/j.jid.2015.11.008
– volume: 32
  start-page: 193
  year: 2014
  end-page: 209
  ident: CR2
  article-title: New insights on keloids, hypertrophic scars, and striae
  publication-title: Dermatol. Clin.
  doi: 10.1016/j.det.2013.11.002
– volume: 2013
  start-page: 423147
  year: 2013
  ident: CR24
  article-title: Models of abnormal scarring
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2013/423147
– volume: 11
  year: 2021
  ident: 1045_CR26
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-84982-4
– volume: 11
  start-page: 603187
  year: 2020
  ident: 1045_CR34
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.603187
– volume: 117
  start-page: 1177
  year: 1991
  ident: 1045_CR9
  publication-title: Arch. Otolaryngol. Head Neck Surg.
  doi: 10.1001/archotol.1991.01870220125023
– volume: 55
  start-page: 214
  year: 1993
  ident: 1045_CR21
  publication-title: J. Surg. Res.
  doi: 10.1006/jsre.1993.1132
– volume: 26
  start-page: 23
  year: 1991
  ident: 1045_CR7
  publication-title: Connect. Tissue Res.
  doi: 10.3109/03008209109152161
– volume: 8
  start-page: e60335
  year: 2013
  ident: 1045_CR22
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0060335
– volume: 2013
  start-page: 423147
  year: 2013
  ident: 1045_CR24
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2013/423147
– volume: 157
  start-page: 104
  year: 2009
  ident: 1045_CR30
  publication-title: Clin. Exp. Immunol.
  doi: 10.1111/j.1365-2249.2009.03933.x
– volume: 2011
  start-page: 345803
  year: 2011
  ident: 1045_CR16
  publication-title: Clin. Dev. Immunol.
  doi: 10.1155/2011/345803
– volume: 8
  start-page: 371
  year: 2000
  ident: 1045_CR18
  publication-title: Wound Repair Regen.
  doi: 10.1111/j.1524-475X.2000.00371.x
– volume: 29
  start-page: 672
  year: 1989
  ident: 1045_CR8
  publication-title: J. Trauma
  doi: 10.1097/00005373-198905000-00023
– volume: 34
  start-page: 14
  year: 2016
  ident: 1045_CR15
  publication-title: Clin. Exp. Rheumatol.
– volume: 54
  start-page: 1679
  year: 2005
  ident: 1045_CR38
  publication-title: Gut
  doi: 10.1136/gut.2005.068593
– volume: 179
  start-page: 549
  year: 1985
  ident: 1045_CR6
  publication-title: Proc. Soc. Exp. Biol. Med.
  doi: 10.3181/00379727-179-RC3
– volume: 12
  start-page: 187
  year: 2017
  ident: 1045_CR29
  publication-title: Annu. Rev. Pathol.
  doi: 10.1146/annurev-pathol-052016-100332
– volume: 8
  start-page: e75600
  year: 2013
  ident: 1045_CR28
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0075600
– volume: 12
  start-page: 810290
  year: 2021
  ident: 1045_CR32
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.810290
– volume: 2020
  start-page: 3608372
  year: 2020
  ident: 1045_CR10
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2020/3608372
– volume: 10
  start-page: 1810
  year: 2019
  ident: 1045_CR1
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.01810
– volume: 32
  start-page: 193
  year: 2014
  ident: 1045_CR2
  publication-title: Dermatol. Clin.
  doi: 10.1016/j.det.2013.11.002
– volume: 268
  start-page: 431
  year: 2018
  ident: 1045_CR12
  publication-title: Ann. Surg.
  doi: 10.1097/SLA.0000000000002926
– volume: 136
  start-page: 507
  year: 2016
  ident: 1045_CR33
  publication-title: J. Investig. Dermatol.
  doi: 10.1016/j.jid.2015.11.008
– volume: 183
  start-page: 4693
  year: 2009
  ident: 1045_CR20
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0802626
– volume: 5
  start-page: 278
  year: 2007
  ident: 1045_CR23
  publication-title: Int. J. Surg.
  doi: 10.1016/j.ijsu.2006.04.007
– volume: 302
  start-page: 319
  year: 2010
  ident: 1045_CR3
  publication-title: Arch. Dermatol. Res.
  doi: 10.1007/s00403-009-1014-y
– volume: 13
  start-page: 888719
  year: 2022
  ident: 1045_CR14
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.888719
– volume: 14
  start-page: 2465
  year: 2021
  ident: 1045_CR19
  publication-title: J. Inflamm. Res.
  doi: 10.2147/JIR.S312091
– volume: 15
  start-page: 122
  year: 2007
  ident: 1045_CR4
  publication-title: Wound Repair Regen.
  doi: 10.1111/j.1524-475X.2006.00193.x
– volume: 164
  start-page: 83
  year: 2011
  ident: 1045_CR27
  publication-title: Br. J. Dermatol.
  doi: 10.1111/j.1365-2133.2010.10048.x
– volume: 4
  start-page: e7798
  year: 2009
  ident: 1045_CR36
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0007798
– volume: 68
  start-page: 473
  year: 2016
  ident: 1045_CR13
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.39443
– volume: 188
  start-page: 1693
  year: 2018
  ident: 1045_CR35
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2018.04.005
– volume: 43
  start-page: 664
  year: 2020
  ident: 1045_CR5
  publication-title: Inflammation
  doi: 10.1007/s10753-019-01148-1
– volume: 175
  start-page: 503
  year: 1992
  ident: 1045_CR31
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.175.2.503
– volume: 225
  start-page: 189
  year: 1989
  ident: 1045_CR40
  publication-title: Anat. Rec.
  doi: 10.1002/ar.1092250303
– volume: 40
  start-page: 380
  year: 2013
  ident: 1045_CR11
  publication-title: J. Dermatol.
  doi: 10.1111/1346-8138.12116
– volume: 8
  start-page: 77
  year: 2019
  ident: 1045_CR25
  publication-title: Adv. Wound Care (New Rochelle)
  doi: 10.1089/wound.2018.0828
– volume: 294
  start-page: F697
  year: 2008
  ident: 1045_CR37
  publication-title: Am. J. Physiol. Renal Physiol.
  doi: 10.1152/ajprenal.00016.2008
– volume: 6
  start-page: 101
  year: 2007
  ident: 1045_CR39
  publication-title: Inflamm. Allergy Drug Targets
  doi: 10.2174/187152807780832265
– volume: 173
  start-page: 310
  year: 2006
  ident: 1045_CR17
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.200502-244OC
SSID ssj0025474
Score 2.4109147
Snippet Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals....
Abstract Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1713
SubjectTerms 13/107
13/31
13/51
14/19
38/77
64/60
692/308/1426
692/420/2780/2152/1566/1618
82/80
96/21
Animal models
Biomedical and Life Sciences
Biomedicine
Chemokines
Helper cells
Hypoxia-inducible factor 1a
Immunodeficiency
Inflammation
Interleukin 17
Interleukin 2 receptors
Lesions
Leukocyte migration
Leukocytes (mononuclear)
Lymphocytes T
Medical Biochemistry
Microenvironments
Molecular Medicine
Patients
Quality of life
Scars
Skin
Stem Cells
Transplantation
Xenografts
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLoi2PQEFGQggEURM_YptbgVYVqKgHKu0tihO7RGyTig3PX8TPZMb2LizPC9f1ZG15PsffN56MCbnnKxQFqsylaapcKNApppA6944rZZXuhMfQwNGr6vBEvJjJ2Q9XfWFOWCwPHCdut2PwalCV5S3XwmllWqNhU5fGAfXwsdg27HlLMZWklhRKpE9kCq53FyVjCpNtMXcISExerW1DoVr_7yjmr5mSPx2Xhl3o4Aq5nOgj3YvD3iQX3LBFtvcGkM5nn-l9GhI6Q6R8i1w8Sufm2-TrPpDAEG_CYCAdPW1ouJ2v_-I6iurf0XAnDja9dfOx72g6ullQD1AZP8JwKJBFetafRtCgaarKSnv8ysRRPAVY0GkMhnOHgbgn9Dja5B1g_QP0lv7-kxswM8xP9MHx85ezh7H_q-TkYP_1s8M83dGQt1KUU664s6JpZCs73ZRFW-rOOethXStjrGeFbpgrQQlby9pCVVIZ2RgugWga72zLr5GNYRzcDUI5SE0H_AkYJhPSW9MC-XFd0XjLPe9YRsqly-o2FTDHezTmdThI57qObq7BzXVwc11l5NHqmfNYvuOv1k8RCStLLL0dfgBA1gmQ9b8AmZGdJY7q9D5Y1FgmUEnUwhm5u2qGlYyOaQYHfgYbkObKgN7LyPUIu9VIuJJM6Apa9Bog14a63jL0b0K1cKzFASwNOn68xO73cf15Lm7-j7m4RS6xsOgwYXKHbEzv3rvbQOImeyes1282KELA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIhLBS3QLQUZCSEQRE3iOLa5oAKtKlBRD1TamxU7donYJqUJz1_Ez2TG8e5qefQazybOzmf7m0dmCHnkSzQKRJZwVZVJIcBOUSmXiXdMCCNkXXh0DRy9Lw9PirdTPo0Otz6mVc73xLBR151FH_kuFloTHK2Jl-efE-wahdHV2ELjKrmGpcsQ1WK6NLh4EaowZ0AxEgbnVvxoJmVyt4eLAtNvMZsIaE1SrhxMoX7_v0jn37mTfwRQw7l0cJOsR0JJ90YE3CJXXLtBNvdaMKbPftDHNKR4Bt_5Brl-FCPpm-TXPtDC4IFC9yDtPK1o6NfX_HQ1RX-Ao6FLDg59crOuqWkM5vTUA3i6bzAdCvSRnjWnI4xQNNZppQ1-d-IoxgV6OnRBcObQNfeCHo8ySQ3o_wpPi7f_7lrMFfMDfXL85t306fj82-TkYP_D68Mkdm1ILC-yIRHMmaKquOW1rLLUZrJ2znhY6UIp4_NUVrnLwDY2JrepKLlQvFKMA_VU3hnL7pC1tmvdFqEMjE8HjAo4Z15wb5QFOuTqtPKGeVbnE5LNVaZtLGmOnTVmOoTWmdSjmjWoWQc163JCni1-cz4W9LhU-hUiYSGJxbjDhe7iVMe1rescTi9RGmaZLJwUyioJvJMrB-zYp3CTnTmOdNwher3E84Q8XAzD2kbFVK0DPYMMGOtCgQU4IXdH2C1mwgTPC1nCiFwB5MpUV0fa5mOoH47VOYC3wYOfz7G7nNf__4vty1_jHrmRh-WEyZE7ZG24-OLuA2EbzIOwKn8D2348nA
  priority: 102
  providerName: ProQuest
Title Establishment of a humanized mouse model of keloid diseases following the migration of patient immune cells to the lesion: Patient-derived keloid xenograft (PDKX) model
URI https://link.springer.com/article/10.1038/s12276-023-01045-6
https://www.ncbi.nlm.nih.gov/pubmed/37524866
https://www.proquest.com/docview/2859756448
https://www.proquest.com/docview/2844679826
https://pubmed.ncbi.nlm.nih.gov/PMC10474158
https://doaj.org/article/d2eac76b3c384e879c9883959e193f06
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3bbtQwELV6kRAvCFouC2VlJIRAEDXxJbZ52y5bVYtarYBK-xbFiV0i2gR1w_WL-EzGjhO0UJB4WimexLOZcXxmPD5G6LFNXVAgkoirPI2YgDhFxVxG1lAhtJAlsy41cHySHp2y-ZIvNxDp98L4on1Paek_03112P4qIUS4cllX_QMwJEo30bajagff3p5M5m_nQ5jFmWBhe0xM5RV3rk1Bnqn_Knj5Z5Xkb0ulfgY6vIluBOiIJ52yt9CGqXfQ7gT-R3PxDT_BvpjTZ8l30LXjsGa-i37MAAD6XJNLBOLG4hz7k_mq76bELvI32J-H45o-mPOmKnFYtllhC27SfAF1MABFfFGddQ7jRAMjK67cDhOD3QrACreNF4R3CVIv8aKTiUrw88_QW3j8V1O7qjDb4qeLV6-Xz7r-b6PTw9m76VEUzmeICs6SNhLUaJbnvOClzJO4SGRpjLYwpoVS2pJY5sQkEAVrTYpYpFwonivKAWQqa3RB76CtuqnNPYQphJkGsBOgS8K41aoA4GPKOLeaWlqSEUp6k2VFIC93Z2icZ34RncqsM3MGZs68mbN0hJ4P93zsqDv-KX3gPGGQdLTb_kJzeZYFN8xKAvOUSDUtqGRGClUoCQiTKwM42MbwkL3ej7LwLVhljiJQcBcHj9CjoRlGsTNMXhuwM8hAWC4UxHojdLdzu0ETKjhhMoUWueaQa6qut9TVe88U7ng4AKFBxy963_2l19_fxf3_E3-ArhM_vFxZ5B7aai8_mYcA1Vo9RptiKcZhhMLvwexk8QauTtPp2Kc_fgJTET4E
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkGAvCDZghQFGAgSCaElsxzYSQoNt6ug67WGT-mbyYY-KLhlrYYy_iCf-Ru6cpFX52Nte46vj9M7n3334jpAnLkGjQEaB0GkScAl2ig6FCpxlUmZSFdyha6C_l3QP-YeBGCyQX-1dGEyrbHWiV9RFlaOPfB0LrUmB1sTbky8Bdo3C6GrbQqMWi549PwOTbfxmZxP4-zSOt7cO3neDpqtAkAseTQLJbMbTVOSiUGkU5pEqrM0cSKLUOnNxqNLYRmC7ZVmcg5UvpBapZgKgkXY2yxnMe4VchYM3RGNPDmYGnuC-6nMEkCZgcE42l3RCptbH8FBiui9mLwGMCpK5g9D3C_gXyP07V_OPgK0_B7dvkhsNgKUbtcTdIgu2XCYrGyUY78fn9Bn1KaXeV79MrvWbyP0K-bkFMNR7vNAdSStHU-r7Aw5_2IKi_8FS35UHhz7bUTUsaBM8GlMHwlqdwXIowFV6PDyqxRZJm7qwdIj3XCzFOMSYTipPOLLoCnxN92uaoIDd9g3e1kz_3ZaYm-Ym9Pn-Zm_won7_bXJ4Kfy8QxbLqrSrhDIwdi0gOMC4MRcu0znAL1uEqcuYY0XcIVHLMpM3JdSxk8fI-FA-U6ZmswE2G89mk3TIy-lvTuoCIhdSv0NJmFJi8W__oDo9Mo0uMUUMp6VMMpYzxa2SOtcKcK7QFtC4C2GStVaOTKORxma2fzrk8XQYdAkyJi0t8BloOMeoXAxT3K3FbroSJkXMVQIjak4g55Y6P1IOP_l65VgNBHAivPhVK7uzdf3_v7h38Wc8Ite7B_1ds7uz17tPlmK_tTAxc40sTk6_2gcAFifZQ79DKfl42SrhN81_eZk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGJ018QbDxUhhgJEAgFjWx49hBQmijrTbKqgoxqd9CXuxR0SVjLYzxi_gN_DruHKdTedm3fY2vjtM7n5978R0hj02ERoEMPBGnkRdKsFNiXyjPaC5lJlURGnQN7A-j3YPw7ViMV8iv5i4MplU2OtEq6qLK0UfewUJrUqA10TEuLWLU7b8-_uJhBymMtDbtNGoRGeizUzDfZq_2usDrJ4z1ex_e7Hquw4CXizCYe5LrLExTkYtCpYGfB6rQOjMglTKOM8N8lTIdgB2XZSwHi1_IWKQxFwCTYqOznMO8V8iqRKuoRVZ3esPR-4W5J0JbAzoAgONxODXdlR2fq84MHkpM_sVcJgBVXrR0LNruAf-CvH9nbv4RvrWnYv86uebgLN2u5e8GWdHlOtnYLsGUPzqjT6lNMLWe-3Wytu_i-BvkZw9AqfV_oXOSVoam1HYLnPzQBUVvhKa2Rw8OfdbTalJQF0qaUQOiW53CciiAV3o0OayFGEldlVg6wVsvmmJUYkbnlSWcanQMvqSjmsYrYO99g7e56b_rEjPVzJw-G3UH4-f1-2-Sg0vh6C3SKqtS3yGUg-mrAc8B4mWhMFmcAxjThZ-ajBtesDYJGpYluSuojn09pokN7HOV1GxOgM2JZXMStcmLxW-O63IiF1LvoCQsKLEUuH1QnRwmTrMkBYOzU0YZz7kKtZJxHitAvSLWgM2ND5NsNnKUOP00S853U5s8WgyDZkHGpKUGPgNNGGKMjsEUt2uxW6yES8FCFcGIWhLIpaUuj5STT7Z6OdYGAdQIL95qZPd8Xf__L-5e_BkPyRqog-Td3nBwj1xldmdhluYmac1Pvur7gBzn2QO3RSn5eNla4TcG3H80
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Establishment+of+a+humanized+mouse+model+of+keloid+diseases+following+the+migration+of+patient+immune+cells+to+the+lesion%3A+Patient-derived+keloid+xenograft+%28PDKX%29+model&rft.jtitle=Experimental+%26+molecular+medicine&rft.au=Lee%2C+A+Ram&rft.au=Lee%2C+Seon-Yeong&rft.au=Choi%2C+Jeong+Won&rft.au=Um%2C+In+Gyu&rft.date=2023-08-01&rft.issn=2092-6413&rft.eissn=2092-6413&rft.volume=55&rft.issue=8&rft.spage=1713&rft.epage=1719&rft_id=info:doi/10.1038%2Fs12276-023-01045-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s12276_023_01045_6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2092-6413&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2092-6413&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2092-6413&client=summon